Search company, investor...

Founded Year

2015

Stage

Acq - Fin | Alive

Total Raised

$111M

Valuation

$0000 

About Unchained Labs

Unchained Labs focuses on providing solutions in the biologics and gene therapy sectors. The company assists in the preparation, processing, and characterization of samples, including tools for stability screening, viscosity measurement, quantification, and buffer exchange. It primarily caters to the life science research industry. It was founded in 2015 and is based in Pleasanton, California.

Headquarters Location

6870 Koll Center Parkway

Pleasanton, California, 94566,

United States

925-587-9800

Loading...

Loading...

Unchained Labs Patents

Unchained Labs has filed 20 patents.

The 3 most popular patent topics include:

  • biotechnology
  • molecular biology
  • fluid dynamics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/21/2018

2/6/2024

Buffers, Molecular biology, Biotechnology, Protein methods, Chromatography

Grant

Application Date

3/21/2018

Grant Date

2/6/2024

Title

Related Topics

Buffers, Molecular biology, Biotechnology, Protein methods, Chromatography

Status

Grant

Latest Unchained Labs News

Exosome Research Market Worth $356 Million | MarketsandMarkets™

Jan 17, 2024

| MarketsandMarkets™ News provided by Share this article Share toX CHICAGO, Jan. 17, 2024 /PRNewswire/ -- Exosome Research Market  in terms of revenue was estimated to be worth $169 million in 2023 and is poised to reach $356 million by 2028, growing at a CAGR of 16.0% from 2023 to 2028 according to a new report by MarketsandMarkets™. Growing interest in exosome-based therapies, and the rising prevalence of chronic diseases like cancer has attracted substantial funding and investment from both public and private sources. This financial support is crucial for research and development efforts. However, regulatory uncertainty in exosome research is the factor restraining market growth. Browse in-depth TOC on "Exosome Research Market" 217 - Tables Market Size Available for Segments Covered Geographies Covered Report Highlights Key Market Opportunities Key Market Drivers Rising cancer prevalence The reagents & kits segment accounted for the largest share by product & service in the exosome research market in 2022. By products & services, the exosome research market has been categorized in reagents & kits, instruments, and services. The kits and reagents segment is further categorized as antibodies, isolation, purification, quantitation kits & reagents, and other kits & reagents. The kits & reagents segment accounted for the largest share of the global exosome research market in 2022. The large share of this segment can primarily be attributed to increasing demand for diagnostic procedures in chronic diseases, and commercial applications of exosomes. The biomarkers segment accounted for the largest share in the application segment in 2022. Based on the application, the global exosome research market is segmented into tissue regeneration, biomarkers, vaccine development, and other applications. In 2022, the other applications segment is expected to grow at the highest growth rate in the forecast period. The growth of this segment is mainly attributed to the increased funding for the diagnostics and treatments of other diseases. The academic & research institute segment accounted for the largest share of the end user segment in the exosome research market in 2022. Based on end users, the exosome research market has been segmented into academic research institutes, pharmaceutical & biotechnology companies, and hospitals & clinical testing laboratories. In 2022, the academic & research institutes, segment accounted for the largest share of the exosome research market. One of the major factors driving the growth of this segment is that exosomes hold immense potential in diagnostics and therapeutics, including drug delivery and regenerative medicine. The enthusiasm surrounding these potential applications has fueled increased research efforts within academic and research institutions. The North American region catered for the largest share of the exosome research market in 2022. The exosome research market is segmented into North America, Europe, the Asia Pacific (APAC), Rest of World. The availability of funding, both public and private key companies, plays an important part in the development and commercialization of advanced technologies. Further, advanced healthcare infrastructure, robust research ecosystem, significant investments in biotechnology, supportive government policies, and a favorable regulatory environment collectively foster the development and commercialization of exosome-based solutions. Exosome Research Market Dynamics: Opportunities: Challenge: Key Market Players of Exosome Research Industry: Key players in the exosome research market include Thermo Fisher Scientific, Inc. (US), Bio-Techne (US), System Biosciences, LLC (US), QIAGEN (Germany), Lonza (Switzerland), NX Pharmagen (US), NanoSomiX (US), Miltenyi Biotech (Germany), Norgen Biotek Corp. (Canada), AMSBio (UK), Aethlon Medical, Inc. (US), Anjarium Biosciences AG (UK), Ciloa (France), InnovaPrep LLC (US), Creative Medical Technologies Holdings, Inc. (US), ILIAS Biologics, Inc. (South Korea), Unchained Labs (US), Rion, Inc. (US), Cell Guidance System, LLC (UK), INOVIQ (Australia), Danaher Corporation (US), Exopharm (Australia), Everzom (France), RoosterBio, Inc. (US), and Creative Biolabs (US). The primary interviews conducted for this report can be categorized as follows: By Respondent: Supply Side- 70% and Demand Side 30% By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25% By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5% Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=224782498 Exosome Research Market - Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall exosome research market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges. The report provides insights on the following pointers: Analysis of key drivers (Increasing investment in pharmaceutical and life sciences research, rising cancer prevalence, increasing interest in exosome-based procedures), restraints (Technical complexity of exosome isolation and technological limitations, regulatory uncertainty in exosome research), opportunities (Rising investments in emerging countries for exosome research, growing interest in exosome-based therapeutics, increasing demand for personalized medicine), and challenges (Lack of gold standard protocols for development & production of exosomes, limited understanding of cargo loading) influencing the growth of the market. Product Development/Innovation: Detailed insights on newly launched products in the exosome research market Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions. Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the exosome research market Competitive Assessment: Thermo Fisher Scientific, Inc. (US), Bio-Techne (US), System Biosciences, LLC (US), QIAGEN (Germany), Lonza (Switzerland), NX Pharmagen (US), NanoSomiX (US), Miltenyi Biotech (Germany), Norgen Biotek Corp. (Canada), AMSBio (UK), Aethlon Medical, Inc. (US), Anjarium Biosciences AG (UK), Ciloa (France), InnovaPrep LLC (US), Creative Medical Technologies Holdings, Inc. (US), ILIAS Biologics, Inc. (South Korea), Unchained Labs (US), Rion, Inc. (US), Cell Guidance System, LLC (UK), INOVIQ (Australia), Danaher Corporation (US), Exopharm (Australia), Everzom (France), RoosterBio, Inc. (US), and Creative Biolabs (US). Related Reports: About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. Contact:

Unchained Labs Frequently Asked Questions (FAQ)

  • When was Unchained Labs founded?

    Unchained Labs was founded in 2015.

  • Where is Unchained Labs's headquarters?

    Unchained Labs's headquarters is located at 6870 Koll Center Parkway, Pleasanton.

  • What is Unchained Labs's latest funding round?

    Unchained Labs's latest funding round is Acq - Fin.

  • How much did Unchained Labs raise?

    Unchained Labs raised a total of $111M.

  • Who are the investors of Unchained Labs?

    Investors of Unchained Labs include Carlyle, Silicon Valley Bank, Canaan Partners, Novo Ventures, TPG Biotech and 4 more.

  • Who are Unchained Labs's competitors?

    Competitors of Unchained Labs include Fluence Analytics.

Loading...

Compare Unchained Labs to Competitors

AspenTech Logo
AspenTech

AspenTech (NASDAQ: AZPN) provides asset management software. It offers enterprise asset performance management, asset performance monitoring, and asset optimization solutions. It serves industries such as food and beverage, transportation, metals and mining, and more. It was founded in 1981 and is based in Bedford, Massachusetts.

F
Fluence Analytics

Fluence Analytics operates as a manufacturer of industrial and laboratory monitoring solutions that produce continuous data streams. The company has two product lines, ACOMP and ARGEN. It primarily caters to biopharmaceutical industries and research facilities. The company was founded in 2012 and is based in Stafford, Texas. In February 2023, Fluence Analytics was acquired by Yokogawa Electric. The terms of the transaction were not disclosed.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.